Multi-Plasmid Influenza Virus Production System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing influenza vaccines face challenges such as dependence on embryonated hen's eggs, limited flexibility, and inefficiencies in producing strains that do not replicate well in eggs, as well as the lack of suitable systems for generating attenuated and temperature-sensitive influenza B virus strains for live attenuated vaccines.
Innovation Solution
A multi-plasmid system for producing recombinant and reassortant influenza viruses, including attenuated and temperature-sensitive strains, by introducing specific amino acid substitutions and using bi-directional expression vectors to introduce influenza B virus genome segments into host cells, allowing for the generation of influenza B virus entirely from cloned cDNA and the production of live attenuated vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If influenza vaccine strains are produced in embryonated hen's eggs, then vaccine production can be achieved, but the process lacks flexibility and efficiency for strains that do not replicate well in eggs
Solution Approach 1:
The patent uses cell culture systems as an intermediary method between traditional egg-based production and direct viral propagation. By introducing influenza virus strains into cell cultures (such as MDCK cells), the system enables production of strains that do not replicate efficiently in eggs, thereby increasing versatility while maintaining productivity
Solution Approach 2:
The patent modifies viral parameters by introducing specific amino acid substitutions (such as H275Y for oseltamivir resistance, E119V for replication enhancement) to create virus strains with improved replication characteristics in cell culture systems, allowing production of strains that would otherwise be unsuitable for vaccine manufacturing
2Productivity
If specific amino acid substitutions are introduced to improve viral replication, then replication capability increases, but the complexity of virus engineering increases
Solution Approach 1:
The patent segments the influenza virus genome into eight separate plasmids, each containing a specific gene segment. This allows independent manipulation and optimization of individual genes (such as HA, NA, PB2) without affecting the entire virus, thereby managing engineering complexity while achieving desired replication improvements through targeted amino acid substitutions
Solution Approach 2:
The patent performs preliminary engineering by introducing desired amino acid substitutions into plasmid sequences before virus assembly. This allows optimization of viral properties (such as replication efficiency and drug resistance) to be established in advance, simplifying the overall engineering process by separating design from assembly
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics.